British Journal of Cancer · 2014 · 110 citations · 46 references
MedicineMolecular BiologyOncologyCarcinogenesisMetastasisMolecular OncologyCancer ProgressionCell Adhesion In MetastasisCell Adhesion ReceptorsEpithelial-mesenchymal TransitionEpithelial-to-mesenchymal TransitionProstate CancerAdhesion ReceptorsEpithelial TransitionEpithelial-mesenchymal Transition In CancerEpithelial-mesenchymal Transition MarkersMetastatic MechanismsMicrorna Regulation Of EmtOncogenic DysregulationProstate Carcinogenesis
BACKGROUND: Expression of epithelial cell adhesion molecule (EpCAM) is deregulated in epithelial malignancies. Beside its role in cell adhesion, EpCAM acts as signalling molecule with tumour-promoting functions. Thus, EpCAM is part of the molecular network of oncogenic receptors and considered an interesting therapeutic target. METHODS: Here, we thoroughly characterised EpCAM expression on mRNA and protein level in comprehensive tissue studies including non-cancerous prostate specimens, primary tumours of different grades and stages, metastatic lesions, and therapy-treated tumour specimens, as well as in prostate cancer cell lines. RESULTS: Epithelial cell adhesion molecule was overexpressed at mRNA and at protein level in prostate cancer tissues and cell lines. Altered EpCAM expression was an early event in prostate carcinogenesis with an upregulation in low-grade cancers and further induction in high-grade tumours and metastatic lesions. Interestingly, EpCAM was repressed upon induction of epithelial-to-mesenchymal transition (EMT) following chemotherapeutic treatment with docetaxel. Oppositely, re-induction of the epithelial phenotype through miRNAs miR-200c and miR-205, two inducers of mesenchymal-to-epithelial transition (MET), led to re-induction of EpCAM in chemoresistant cells. Furthermore, we prove that EpCAM cleavage, the first step of EpCAM signalling takes place in prostate cancer cells but in contrast to other cancer entities, EpCAM has no measurable impact on the proliferative behaviour of prostate cells, in vitro. CONCLUSIONS: In conclusion, our data confirm that EpCAM overexpression is an early event during prostate cancer progression. Epithelial cell adhesion molecule displays a dynamic, heterogeneous expression and associates with epithelial cells rather than mesenchymal, chemoresistant cells along with processes of EMT and MET.
46
Recurrent Fusion of <i>TMPRSS2</i> and ETS Transcription Factor Genes in Prostate Cancer
Scott A. Tomlins, Daniel R. Rhodes, Sven Perner et al. · Science · 2005 · 3.9K citations
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Daniel R. Rhodes, Jianjun Yu, K. Shanker et al. · Neoplasia · 2004 · 3.7K citations · Full text
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Sunitha Nagrath, Lecia V. Sequist, Shyamala Maheswaran et al. · Nature · 2007 · 3.5K citations · Full text
Medicine, Cancer Biology, Oncology +15